Allspring Global Investments Holdings LLC lessened its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 729,683 shares of the company’s stock after selling 12,864 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.37% of BridgeBio Pharma worth $48,823,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. First Bank & Trust raised its holdings in BridgeBio Pharma by 1.6% during the 2nd quarter. First Bank & Trust now owns 8,797 shares of the company’s stock valued at $655,000 after acquiring an additional 142 shares during the period. SBI Securities Co. Ltd. boosted its holdings in shares of BridgeBio Pharma by 55.3% in the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock worth $29,000 after acquiring an additional 157 shares during the period. Covestor Ltd boosted its holdings in shares of BridgeBio Pharma by 7.6% in the third quarter. Covestor Ltd now owns 2,252 shares of the company’s stock worth $149,000 after acquiring an additional 159 shares during the period. North Dakota State Investment Board boosted its holdings in shares of BridgeBio Pharma by 3.9% in the third quarter. North Dakota State Investment Board now owns 5,177 shares of the company’s stock worth $341,000 after acquiring an additional 196 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of BridgeBio Pharma by 13.8% in the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company’s stock valued at $123,000 after purchasing an additional 199 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.
BridgeBio Pharma Stock Up 0.9%
BridgeBio Pharma stock opened at $78.67 on Wednesday. BridgeBio Pharma, Inc. has a fifty-two week low of $62.06 and a fifty-two week high of $93.42. The firm’s fifty day moving average price is $69.83 and its 200-day moving average price is $72.78.
Insiders Place Their Bets
In related news, CEO Neil Kumar sold 34,980 shares of BridgeBio Pharma stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $82.53, for a total value of $2,886,899.40. Following the transaction, the chief executive officer owned 243,327 shares in the company, valued at $20,081,777.31. This trade represents a 12.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $72.85, for a total value of $145,700.00. Following the transaction, the chief accounting officer directly owned 120,687 shares in the company, valued at $8,792,047.95. This trade represents a 1.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 56,980 shares of company stock worth $4,563,699. 14.23% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the company. Piper Sandler boosted their price objective on BridgeBio Pharma from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. Weiss Ratings cut BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, September 25th. Citigroup dropped their price objective on BridgeBio Pharma from $94.00 to $91.00 and set a “neutral” rating on the stock in a report on Monday, October 19th. Bank of America raised their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Nineteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $104.26.
Get Our Latest Stock Report on BBIO
About BridgeBio Pharma
BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.
Read More
- Five stocks we like better than BridgeBio Pharma
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
